Abstract
HLA-E-restricted HIV-specific T cells offer exciting possibilities for immunotherapy. However, HLA-E binding peptides are rare. A recent study showed that in HLA-B*57:01 people living with HIV (PLWH), the peptide that dominates the T cell response, KAFSPEVIPMF (KF11), also stimulates HLA-E-restricted T cells, even though direct binding of this peptide to HLA-E could not be demonstrated. We therefore changed position 2 alanine for methionine in the peptide (referred to as KMF11) which greatly enhanced binding to HLA-E. This enabled the generation of stabilised HLA-E-KMF11 tetramers which were used to select and then grow specific T cell clones from T cells of HLA-B*57:01 negative blood donors primed with this peptide in vitro. Approximately 20% of these T cell clones reacted with HLA-E positive cells presenting the native KF11 peptide. Furthermore, these T cells inhibited replication of HIV-1 NL4-3 in CD4 T cells in vitro. Therefore, this native peptide can be presented by HLA-E to CD8 T cells, although priming in vivo may depend on cross reactivities to classical MHC Ia types. Nevertheless, such T cells could be exploitable for immunotherapy given the conservation of this HIV1 peptide epitope and the non-polymorphism in HLA-E.
Authors
Hong Sun, Hongbing Yang, Max N. Quastel, Simon Brackenridge, Wanlin He, Anna E. Kliszczak, Margarida Rei, Persephone Borrow, Geraldine M. Gillespie, Andrew J. McMichael
